Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Pharmacology, Toxicology and Pharmaceutical Science
1
13%
Biochemistry, Genetics and Molecular Biology
1
13%
Immunology and Microbiology
1
13%
Earth and Planetary Sciences
1
13%
Other
0
0%
Unknown
2
25%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2021.
All research outputs
#4,291,488
of 23,308,124 outputs
Outputs from Journal of Clinical Oncology
#7,934
of 20,288 outputs
Outputs of similar age
#86,387
of 351,268 outputs
Outputs of similar age from Journal of Clinical Oncology
#179
of 560 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,288 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.8. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,268 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 560 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
